Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy

Natacha C Villegas, Wen-Shin Lee Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USACorrespondence: Natacha C VillegasDepartment of Ophthalmology, Stanford University, Medical Center, 2452 Watson Court, Palo Alto, CA, 94303-5353, USATel +1 832 477-3498Email natacha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Villegas NC, Lee WS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	netarsudil rhopressa maximally tolerated medical therapy glaucoma. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3cbfed0c33da4bf6a7fda5d577a9e67a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3cbfed0c33da4bf6a7fda5d577a9e67a
record_format	dspace
spelling	oai:doaj.org-article:3cbfed0c33da4bf6a7fda5d577a9e67a2021-12-02T19:31:58ZEffectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy1177-5483https://doaj.org/article/3cbfed0c33da4bf6a7fda5d577a9e67a2021-11-01T00:00:00Zhttps://www.dovepress.com/effectiveness-of-netarsudil-as-an-additional-therapy-for-glaucoma-in-p-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Natacha C Villegas, Wen-Shin Lee Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USACorrespondence: Natacha C VillegasDepartment of Ophthalmology, Stanford University, Medical Center, 2452 Watson Court, Palo Alto, CA, 94303-5353, USATel +1 832 477-3498Email natachav@stanford.eduPurpose: This study seeks to evaluate the effectiveness of netarsudil (Rhopressa) in patients with inadequately controlled IOP on otherwise maximally tolerated medical therapy.Methods: This is a retrospective study of patients started on netarsudil at Stanford University. Exclusion criteria included glaucoma surgery or laser within 6 months of starting netarsudil and other modifications to the baseline medication regimen within 4 weeks of starting netarsudil. The primary outcome was treatment success, defined as IOP reduction meeting a predetermined target, and no further medication, laser, or surgery recommended subsequent to starting netarsudil.Results: Sixty-two eyes were included, and 36 (58%) achieved treatment success at first follow-up. Mean baseline IOP was 19.5 ± 5.6 mmHg on a mean of 3.5 ± 0.7 ocular hypotensive medications. The mean change in IOP from baseline to first follow-up was − 3.53 mmHg (− 17%). In patients who achieved treatment success, mean IOP change was − 5.22 mmHg (− 28.0%). Of the eyes with baseline IOP ≤ 20 mmHg, 69% achieved treatment success, compared to only 17% of eyes with baseline IOP ≥ 21 mmHg (P < 0.05).Conclusion: Netarsudil is effective in lowering IOP for patients on otherwise maximally tolerated medical therapy, for which glaucoma laser or surgery would have been the only remaining therapeutic options. Treatment success was more likely in eyes with baseline IOP under 20 mmHg.Keywords: netarsudil, Rhopressa, maximally tolerated medical therapy, glaucomaVillegas NCLee WSDove Medical Pressarticlenetarsudilrhopressamaximally tolerated medical therapyglaucoma.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 4367-4372 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	netarsudil rhopressa maximally tolerated medical therapy glaucoma. Ophthalmology RE1-994
spellingShingle	netarsudil rhopressa maximally tolerated medical therapy glaucoma. Ophthalmology RE1-994 Villegas NC Lee WS Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
description	Natacha C Villegas, Wen-Shin Lee Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USACorrespondence: Natacha C VillegasDepartment of Ophthalmology, Stanford University, Medical Center, 2452 Watson Court, Palo Alto, CA, 94303-5353, USATel +1 832 477-3498Email natachav@stanford.eduPurpose: This study seeks to evaluate the effectiveness of netarsudil (Rhopressa) in patients with inadequately controlled IOP on otherwise maximally tolerated medical therapy.Methods: This is a retrospective study of patients started on netarsudil at Stanford University. Exclusion criteria included glaucoma surgery or laser within 6 months of starting netarsudil and other modifications to the baseline medication regimen within 4 weeks of starting netarsudil. The primary outcome was treatment success, defined as IOP reduction meeting a predetermined target, and no further medication, laser, or surgery recommended subsequent to starting netarsudil.Results: Sixty-two eyes were included, and 36 (58%) achieved treatment success at first follow-up. Mean baseline IOP was 19.5 ± 5.6 mmHg on a mean of 3.5 ± 0.7 ocular hypotensive medications. The mean change in IOP from baseline to first follow-up was − 3.53 mmHg (− 17%). In patients who achieved treatment success, mean IOP change was − 5.22 mmHg (− 28.0%). Of the eyes with baseline IOP ≤ 20 mmHg, 69% achieved treatment success, compared to only 17% of eyes with baseline IOP ≥ 21 mmHg (P < 0.05).Conclusion: Netarsudil is effective in lowering IOP for patients on otherwise maximally tolerated medical therapy, for which glaucoma laser or surgery would have been the only remaining therapeutic options. Treatment success was more likely in eyes with baseline IOP under 20 mmHg.Keywords: netarsudil, Rhopressa, maximally tolerated medical therapy, glaucoma
format	article
author	Villegas NC Lee WS
author_facet	Villegas NC Lee WS
author_sort	Villegas NC
title	Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
title_short	Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
title_full	Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
title_fullStr	Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
title_full_unstemmed	Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
title_sort	effectiveness of netarsudil as an additional therapy for glaucoma in patients already on maximally tolerated medical therapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/3cbfed0c33da4bf6a7fda5d577a9e67a
work_keys_str_mv	AT villegasnc effectivenessofnetarsudilasanadditionaltherapyforglaucomainpatientsalreadyonmaximallytoleratedmedicaltherapy AT leews effectivenessofnetarsudilasanadditionaltherapyforglaucomainpatientsalreadyonmaximallytoleratedmedicaltherapy
_version_	1718376432214736896

Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy

Ejemplares similares